Molecular & cellular toxicology

Changes to mRNA vaccine design that may improve its stability and protein production

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Modifying mRNA structural elements can enhance intracellular stability and translational efficiency.

  • Changes to the 5' cap, untranslated regions, coding region, and polyadenylation tail may reduce mRNA immunogenicity.
  • Improvements in mRNA structural elements are associated with better immune response specificity and intensity.
  • Optimizing these structural components could lead to higher translational potency of mRNA vaccines.
  • Further investigation into mRNA engineering is necessary for advancing vaccine development.

Simplified

Full Text

We can’t show the full text here under this license.
View Full Text ↗

Funding

Competing interests

Conflict of interestAuthor S.C.K. declares that he has no conflict of interest. Author S.S.S. declares that he has no conflict of interest. Author W.-R.S. declares that she has no conflict of interest. Author G.A. declares that she has no conflict of interest. Author B.-K.C. declares that she has no conflict of interest. Author J.-Y.A. declares that she has no conflict of interest. Author Y.-H.K. declares that she has no conflict of interest.
PubMed

Related papers

Apr '21
New possibilities in vaccine technology using mRNA vaccines
cited by 3 papers
journal article
Feb '20
Improving mRNA vaccine performance using special molecule helpers
top 20% journal
cited by 60 papers
research support, non-u.s. gov't
Nov '21
Designing Therapeutic mRNA from Start to Finish
top 1% journal
cited by 48 papers
research support, n.i.h., extramural
Jun '05
How the ends of the dengue virus genome control protein production
top 20% journal
cited by 101 papers
research support, n.i.h., extramural
May '23
How mRNA Vaccines Are Made and Delivered
cited by 17 papers
journal article
Jul '12
Using mRNA to produce proteins from outside sources
top 30% journal
cited by 62 papers
research support, non-u.s. gov't
Jan '01
Structure and function of a translation element active in either the beginning or end non-coding regions of RNA
cited by 74 papers
research support, u.s. gov't, non-p.h.s.
Oct '00
How cells check and start protein-making depending on mRNA start signals and tail
top 50% journal
cited by 1 paper
research support, u.s. gov't, non-p.h.s.
Nov '98
How a tail on yeast messenger RNA helps control protein production
cited by 95 papers
research support, non-u.s. gov't
Sep '01
Stopping production of ceruloplasmin protein needs mRNA to form a loop using the poly(A) tail, its binding protein, and a key translation initiation factor
cited by 51 papers
research support, u.s. gov't, p.h.s.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the mrna technology brief

issue #49
A single antibody-coated nanoparticle edits blood stem cells inside living mice
6 days ago7 studies
issue #48
A new RNA polymerase makes self-amplifying vaccine production 9x easier
1 week ago7 studies
issue #47
Engineers used AI to design a self-destruct switch that kills virus-infected cells on command
2 weeks ago7 studies
issue #46
A simple ligand swap redirected liver-targeting nanoparticles to the lungs with 200-fold more mRNA delivery
3 weeks ago7 studies
issue #45
A $1 device delivers naked mRNA vaccines as effectively as lipid nanoparticles in mice and human skin
4 weeks ago7 studies
issue #44
Light-activated lipid nanoparticles spin their way out of cellular traps to boost cancer vaccine results
5 weeks ago7 studies
issue #43
A common antibiotic switches self-amplifying RNA vaccines on and off — with 10x range between states
6 weeks ago7 studies
issue #42
A single LNP dose achieved 49% liver gene editing in mice — without viral vectors
7 weeks ago7 studies
issue #41
Buffer choice affects mRNA vaccine performance by 40% after freeze-thaw cycles
8 weeks ago7 studies
issue #40
mRNA vaccine boosted cancer immunotherapy survival rates by 70-80% in mice
9 weeks ago7 studies
explore the archive
See more issues from the mrna technology brief